Role of STAT3 Signaling Pathway in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 196
Special Issue Editors
Interests: colorectal cancer; immunotherapy; inflammatory bowel diseases; anti-cancer drugs
Special Issues, Collections and Topics in MDPI journals
Interests: colorectal carcinogenesis; STAT3 signaling; drug repositioning; inflammatory bowel diseases; gut homeostasis; intestinal microbiota; mucosal immunology; inflammasome
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Signal Transducers and Activators of Transcription (STATs) represent a family of seven latent cytoplasmic transcriptional factors (i.e., STAT1, STAT2, STAT3, STAT4, STAT5α, STAT5β, and STAT6) involved in several molecular pathways underlying crucial biological processes.
Among them, STAT3 plays a critical role under physiological conditions, contributing to cell proliferation, survival, and differentiation. However, it is noteworthy that STAT3 persistent activation can sustain cancer onset and progression, and represents an important hallmark in different malignancies (i.e., colon cancer, melanoma, etc). For this reason, STAT3 is considered a very attractive therapeutic target for cancer treatment. Despite several efforts, the modulation of STAT3 activity is still critical and most of the molecular and cellular mechanisms underlying STAT3 signaling need to be better characterized.
In this Special Issue, we invite investigators working on the role of STAT3 in cancer development and progression (covering both basic and more pre-clinical aspects), and potential therapeutic approaches to target its functions, to submit original papers or reviews to shed further light on this field. Potential topics include but are not limited to:
- Novel molecular and cellular mechanisms underlying STAT3 tumorigenic function in cancer development and progression.
- Uncovering novel molecules and/or STAT3-binding proteins to target STAT3 oncogenic functions.
- Therapeutic approaches and clinical interventions to treat cancer patients.
Dr. Carmine Stolfi
Dr. Federica Laudisi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- STAT3 signaling
- STAT3-binding proteins
- cancer
- tumor microenvironment
- gut inflammation
- inflammatory bowel diseases
- mucosal immunology
- cytokines
- epigenetic
- drug repositioning
- natural compounds
